The Korean Journal of Medicine

  • 제82권1호
  • /
  • Pages.37-44
  • /
  • 2012
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

진행성 위암 환자에서 1차 요법으로 FOLFOX-4 병합화학 약물치료의 효과와 안정성

FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer

  • 이천우 (고신대학교 의과대학 내과학교실) ;
  • 박무인 (고신대학교 의과대학 내과학교실) ;
  • 박선자 (고신대학교 의과대학 내과학교실) ;
  • 문원 (고신대학교 의과대학 내과학교실) ;
  • 김형훈 (고신대학교 의과대학 내과학교실) ;
  • 이혜원 (고신대학교 의과대학 내과학교실) ;
  • 구기환 (고신대학교 의과대학 내과학교실) ;
  • 김부경 (고신대학교 의과대학 내과학교실)
  • Lee, Cheon-Woo (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Park, Moo-In (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Park, Seun-Ja (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Moon, Won (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Kim, Hyung-Hun (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Lee, Hae-Won (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Ku, Ki-Hwan (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Kim, Bu-Kyung (Department of Internal Medicine, Kosin University College of Medicine)
  • 발행 : 2012.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 전이성 위암 환자들에서 1차 치료로서 투여된 oxaliplatin, 5-FU, leucovorin (FOLFOX-4) 병합화학요법의 효과와 안정성에 대하여 분석하였다. 방법: 2006년 8월부터 2009년 2월까지 조직학적으로 확진하고 절제가 불가능한 진행, 전이성 위암 환자 35명을 대상으로 의무기록을 통하여 후향적으로 조사하였다. Oxaliplatin $85\;mg/m^2$과 leucovorin $200\;mg/m^2$을 제1일에 2시간 동안 정주하였으며, 5-FU는 $400\;mg/m^2$을 bolus로, $600\;mg/m^2$을 22시간 동안 지속 주입하는 방법으로 제1일과 2일에 투여하였다. 이상을 2주 간격으로 시행하였다. 반응률은 2 내지 3주기의 항암요법 시행 후 평가하였고, 부작용은 NCI CTC ver. 2.0을 기준으로 평가하였다. 결과: 총 35명 환자들의 총 생존기간 중앙값은 8.5개월 (6.23-10.90개월)이었고, 반응지속기간은 4.5개월(0.38-9.75개월)이었다. 치료반응에서 완전관해는 없었고, 부분관해 19예(54.3%), 불변 13예(37.1%), 진행 3예(8.6%)였다. 전체 항암요법 298회 중 grade 3 이상의 백혈구 감소증은 5회(1.6%)였고, 호중구 감소증은 총 27회(9%)였다. Grade 3 이상의 빈혈은 4회(1.3%)였고, 혈소판 감소증은 10회(3.2%)였다. 호중구 감소증에 의한 감염이 있어 1명의 환자가 사망하였다. Grade 1-2 신경병증이 44회(14.7%)에서 나타났다. 결론: FOLFOX-4의 병합화학요법은 수술을 할 수 없는 진행성 위암 환자들에 대한 1차 요법으로 높은 반응률을 보이면서 독성이 약한 비교적 안전한 치료법이다.

Background/Aims: This study examined the efficacy and safety of oxaliplatin-5-fluorouracil-leucovorin (FOLFOX-4) combination chemotherapy as first-line treatment in patients with advanced gastric cancer. Methods: This retrospective study enrolled 35 patients diagnosed with pathologically proven surgically unresectable gastric cancer who received FOLFOX-4 combination chemotherapy between August 2006 and February 2009, using medical records. The administered dose of oxaliplatin was $85\;mg/m^2$ for 2 hrs and leucovorin $200\;mg/m^2$ for 2 hrs on day 1, 5-fluorouracil $400\;mg/m^2$ as a bolus and 5-fluorouracil $600\;mg/m^2$ for 22 hrs on days 1 and 2, every 2 weeks. The response was assessed every three cycles. Toxicity was evaluated for every course of chemotherapy according to the NCI toxicity criteria ver. 2.0. Results: The median patient age was 61 (range 27-77) years. The median overall survival was 8.50 (6.23-10.90) months and the median time to progression was 4.50 (0.38-9.75) months. With FOLFOX-4, there was no complete remission and 19 partial responses, for a response rate of 54.3%. Over 298 cycles, anemia worse than NCI toxicity grade 3 occurred in 1.3%, leukopenia in 1.6%, neutropenia in 9%, and thrombocytopenia in 3.2%. Grade 1-2 neuropathy occurred in 14.7% of the cycles. Neutropenic fever occurred in two cycles and the regimen was changed because of side effects in one cycle. Conclusions: FOLFOX-4 has a very high response rate with mild toxicity in patients with advanced gastric cancer as a first-line treatment.

키워드

참고문헌

  1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. https://doi.org/10.1038/bjc.1995.114
  3. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168. https://doi.org/10.1023/A:1008243606668
  4. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14(Suppl 2):ii41-ii44. https://doi.org/10.1093/annonc/mdg753
  5. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007;33:315-324 https://doi.org/10.1016/j.ctrv.2007.01.004
  6. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008;43:256-264. https://doi.org/10.1007/s00535-008-2177-6
  7. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8: 876-885. https://doi.org/10.1097/00001813-199710000-00009
  8. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947. https://doi.org/10.1200/JCO.2000.18.16.2938
  9. Shin JH, Kim SY, Woo CM, et al. Oxaliplatin and UFT, leucovorin combination chemotherapy in patients with advanced colorectal cancer. Korean J Med 2004;67:58-64.
  10. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 2004;22:229-237. https://doi.org/10.1200/JCO.2004.05.113
  11. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548. https://doi.org/10.1200/JCO.2002.02.021
  12. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658-663. https://doi.org/10.1200/jco.2004.22.14_suppl.658
  13. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005;92:1644-1649. https://doi.org/10.1038/sj.bjc.6602573
  14. Liu ZF, Guo QS, Zhang XQ, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 2008;31:259-263. https://doi.org/10.1097/COC.0b013e31815d43ee
  15. Zhao JG, Qiu F, Xiong JP, et al. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs 2009;20:281-286. https://doi.org/10.1097/CAD.0b013e328324bbc1
  16. Janunger KG, Hafstrom L, Nygren P, Glimelius B; SBUgroup. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001;40:309-326. https://doi.org/10.1080/02841860121271
  17. Choi IS, Oh DY, Kim BS, Lee KW, Kim JH, Lee JS. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res Treat 2007;39:99-103. https://doi.org/10.4143/crt.2007.39.3.99
  18. Keam B, Im SA, Han SW, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008;8:148. https://doi.org/10.1186/1471-2407-8-148
  19. Kang SH, Jeong HY, Kim SH, et al. Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma. Korean J Gastroenterol 2010;55:26-32. https://doi.org/10.4166/kjg.2010.55.1.26
  20. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997. https://doi.org/10.1200/JCO.2006.06.8429
  21. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-5667. https://doi.org/10.1200/JCO.2005.17.376

피인용 문헌

  1. Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer vol.66, pp.1, 2012, https://doi.org/10.4166/kjg.2015.66.1.10
  2. 재발 진행성 위암 환자의 FOLFOX 유발 부작용 개선에 대한 한의 치료 1례 vol.41, pp.1, 2012, https://doi.org/10.22246/jikm.2020.41.1.81